193 related articles for article (PubMed ID: 25555465)
1. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
Sun BS; Li Y; Zhang ZF; You J; Wang CL
Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
[TBL] [Abstract][Full Text] [Related]
5. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
7. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
[TBL] [Abstract][Full Text] [Related]
9. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
10. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.
Takenaka M; Hanagiri T; Shinohara S; Yasuda M; Chikaishi Y; Oka S; Shimokawa H; Nagata Y; Nakagawa M; Uramoto H; So T; Yamada S; Tanaka F
Clin Lung Cancer; 2013 May; 14(3):288-94. PubMed ID: 23122494
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of nuclear factor of activated T-cells 5 expression in non-small cell lung cancer patients who underwent surgical resection.
Cho HJ; Yun HJ; Yang HC; Kim SJ; Kang SK; Che C; Lee SD; Kang MW
J Surg Res; 2018 Jun; 226():40-47. PubMed ID: 29661287
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
13. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
[TBL] [Abstract][Full Text] [Related]
14. Do tumours located in the left lower lobe have worse outcomes in lymph node-positive non-small cell lung cancer than tumours in other lobes?
Kudo Y; Saji H; Shimada Y; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N
Eur J Cardiothorac Surg; 2012 Sep; 42(3):414-9. PubMed ID: 22398463
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.
Schneider S; Yochim J; Brabender J; Uchida K; Danenberg KD; Metzger R; Schneider PM; Salonga D; Hölscher AH; Danenberg PV
Clin Cancer Res; 2004 Mar; 10(5):1588-96. PubMed ID: 15014008
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
[TBL] [Abstract][Full Text] [Related]
18. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
[TBL] [Abstract][Full Text] [Related]
19. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.
Gajra A; Newman N; Gamble GP; Kohman LJ; Graziano SL
J Clin Oncol; 2003 Mar; 21(6):1029-34. PubMed ID: 12637467
[TBL] [Abstract][Full Text] [Related]
20. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer.
Osarogiagbon RU; Allen JW; Farooq A; Berry A; O'Brien T
Ann Thorac Surg; 2011 May; 91(5):1486-92. PubMed ID: 21524460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
